

12th Congress of the EHA, Vienna, Thursday, June 7, 2007

ADDRESS: Neue Messe Vienna, Messeplatz 1, A-1021 Vienna, Austria
ROOM: SCHUBERT IV
TIME: 16.00–18.00

Part I: Status of the planned trials in Ph-positive ALL

Chair: D. Hoelzer

1. **P. Rousselot:** Status of the Dasatinib trial
2. **O. G. Ottmann:** Status of the Nilotinib trial

Part II: Standardisation of methods for lab analysis in the trials for Ph-positive ALL:

Chair: R. Bassan

3. **O. Spinelli:** BCR-ABL determinations and reporting and mutation analysis in the NILG group
4. **S. Soverini:** ABL Kinase domain mutation analysis by D-HPLC of Ph+ ALL patients - Italian experience
5. **I. Iacobucci:** Identification of a novel mechanism of resistance to imatinib and dasatinib in Ph+ ALL: overexpression of aberrantly-spliced oncogenic IKAROS isoforms
6. **H. Pfeifer:** Procedure for BCR-ABL and mutation analysis in the GMALL and proposal for standardisation

Discussion and decision on further procedure (methods, involved labs, lab rounds etc.)